Stigmata of recent haemorrhage and use of endoscopic therapy* at first endoscopy
| % of 5004† (n) | Therapy given (n) | Rebleeding‡ (n) | No therapy given (n) | Rebleeding‡ (n) | |
| Visible vessel | 6.3% (318) | 92% (292) | 28% (82) | 8% (26) | 38% (10) |
| Spurting vessel | 2.9% (145) | 93% (135) | 41% (55) | 7% (10) | 60% (6) |
| Adherent clot | 6.9% (347) | 68% (236) | 32% (76) | 32% (111) | 35% (39) |
| Dark spot in ulcer base | 1.7% (83) | 64% (53) | 15% (8) | 36% (30) | 35% (39) |
| All varices | 11% (526) | 64% (339) | 29% (99) | 36% (184) | 20% (36) |
| Varices with red spot/wheal marking | 2.3% (114) | 92% (105) | 24% (25) | 8% (9) | 0 |
| Varices with nipple sign | 0.4% (18) | 94% (17) | 41% (7) | 6% (1) | 0 |
↵* BSG guidelines (2002) advise endoscopic therapy for actively bleeding ulcers, non bleeding visible vessels and ulcers with adherent clot when technically possible and use of banding in preference to sclerotherapy for varices if possible.
↵† In 62 cases data on whether endoscopic therapy was used was missing.
↵‡ Defined as rebleeding or continued bleeding.